Uncontrolled Gout
VIDEO: Intervention could reduce economic burden, uncontrolled gout in US adults with CKD
PHILADELPHIA — Gout prevalence in U.S. adults with chronic kidney disease is expected to markedly increase during the next 12 years, suggests data presented at ASN Kidney Week.
Amgen to acquire Horizon Therapeutics for $28.3 billion
Amgen Inc., which has established its mark in kidney care as the dominant supplier of anemia treatments, agreed to buy Ireland-based Horizon Therapeutics plc for $28.3 billion in a cash offer.
Rapid Response: Practical Strategies for the Management of Uncontrolled Gout
This activity is supported by an educational grant from Horizon Therapeutics USA, Inc.
VIDEO: Pegloticase, methotrexate treats uncontrolled gout without compromising kidney
ORLANDO — In this video from ASN Kidney Week, Abdul A. Abdellatif, MD, discusses the efficacy of pegloticase treatment in conjunction with methotrexate for patients with uncontrolled gout.
FDA approves pegloticase, methotrexate combo in patients with uncontrolled gout
The FDA has approved the supplemental biologics license application for pegloticase, expanding the drug’s label to include co-administration with methotrexate in patients with uncontrolled gout, according to a press release.